Theravance Biopharma (TBPH) Other Non-Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Other Non-Current Liabilities data on file, last reported at $244000.0 in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $244000.0, down 81.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $244000.0 (down 81.04% YoY), and the FY2025 annual result was $313000.0, down 99.63% from the prior year.
• Other Non-Current Liabilities slipped to $244000.0 in Q1 2026 per TBPH's latest filing, from $313000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $83.7 million in Q4 2024 and troughed at $244000.0 in Q1 2026.
• A 5-year average of $20.5 million and a median of $5.0 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities soared 2301.72% in 2022, then tumbled 99.63% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $76.0 million in 2022, then rose by 4.57% to $79.5 million in 2023, then advanced by 5.32% to $83.7 million in 2024, then plunged by 99.63% to $313000.0 in 2025, then retreated by 22.04% to $244000.0 in 2026.
• Business Quant data shows TBPH's Other Non-Current Liabilities at $244000.0 in Q1 2026, $313000.0 in Q4 2025, and $313000.0 in Q3 2025.